Laurus Labs is a research-driven integrated pharmaceutical company making APIs, generic finished dosage forms and CDMO services across ARV, oncology and emerging therapies like peptides, ADCs and gene therapy. The Q2 FY27 print will speak to whether the 31.8% EBITDA margin of Q1 FY27 holds above the guided 30% floor amid a sharp spike in solvent and crude-linked input costs, and whether the CDMO business sustains its momentum after a 67% YoY jump.
| Results date | October 29, 2026 |
|---|---|
| Quarter | Q2 FY 2026-2027 |
| Previous quarter revenue | Rs. 2,026 Cr |
| Previous quarter PAT | Rs. 368 Cr |
| Previous quarter EBITDA margin | 31.8% |
| Market cap | Rs. 106,441.51 Cr |
| CMP | Rs. 1,970.0 |
The Board of Laurus Labs meets on October 29, 2026 to approve the Q2/H1 FY27 results and consider an Interim Dividend for FY 2026-27 plus record date. The intimation was filed on October 13, 2026, with the trading window closed October 1-31.
The Q2 & H1 FY27 earnings call is scheduled for October 29, 2026 at 5:00 PM IST, hosted by DAM Capital Advisors.
The Board will consider an interim dividend for FY 2026-27, with the record date set for October 29, 2026. No dividend amount has been stated yet.
The central test this quarter is whether EBITDA margin holds above the guided 30% floor from FY27 onwards, after Q1 FY27 printed 31.8% with gross margin at 62.7% against the 'sustain 61.4%' guide. The input-cost backdrop turned adverse inside the quarter — India methanol prices rose 67.64% QoQ in Q2 2026, a 7.5% import duty on solvents was reinstated from July 15 after the customs exemption lapsed, and Brent breached $100/bbl on September 9 — feeding petrochemical-linked raw materials with the roughly one-quarter lag management has described. Management had already flagged solvent prices as the FY27 margin risk while stating, 'We are very confident on maintaining or improving this EBITDA margin in FY 27', and noted margin pressure from global conflicts was 'not that significant'. On the revenue side, CDMO printed Rs. 870 Cr in Q1 (+67% YoY) but commercial supplies land 'once or twice a year rather than monthly', so the quarter's direction hinges on supply timing, while ARV revenue dipped QoQ to Rs. 669 Cr from Rs. 683 Cr against a UNAIDS report that global HIV funding fell nearly a fifth last year. The upcoming call is also likely to cover the updated FY27-FY28 capex number against the Rs. 3,000 Cr guide, the NCLT Composite Scheme status after the September 10, 2026 hearing, and the ADC facility qualification timeline that shifted from mid-2027 to end-2027.
Guidance scorecard: Key management commitments to probe on the call, latest-to-oldest by statement date:
Margin mix and ARV trajectory
Strategic execution and corporate actions
Yes — CEO Satyanarayana Chava said, 'We are very confident on maintaining or improving this EBITDA margin in FY 27.' Q1 FY27 delivered a 31.8% EBITDA margin, above the guided floor of greater than 30% from FY27 onwards.
Management has guided to around Rs. 3,000 crores of capex over FY27 and FY28, up from the earlier Rs. 1,000 Cr plan, and added it 'may do more than that'. Q1 FY27 capex was Rs. 394 Cr, or 19% of revenue, with 94% directed to API/CDMO.
The CFO said funding will come 'both internally and then if needed debt', adding, 'We are not thinking on any dilution on the capex funding side.' Debt/EBITDA stood at 1.3x in FY26 and Q1 FY27.
Management said, 'While we are not giving any concrete numbers for '27, we still expect a healthy growth over whatever we expect to report in '26.' CDMO revenue was Rs. 2,080 Cr in FY26 (+36%) and jumped 67% YoY to Rs. 870 Cr in Q1 FY27, though management has flagged quarterly lumpiness in commercial supplies.
Yes — consolidated revenue rose to Rs. 2,026 Cr in Q1 FY27, up 29% YoY and 12% QoQ, with CDMO up 67% YoY and Generics up 10% YoY. The mix has shifted so that roughly two-thirds of revenue is now non-ARV, which management expects to be the peak ARV share.